Patent US4405616A successfully refreshed from Google Patents.
US4405616A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Penetration enhancers for transdermal drug delivery of systemic agents
Assignee: Discovery Therapeutics Inc
•
Filing: 1982-05-20
•
Granted: 1983-09-20
•
Expires: 2002-05-20
Abstract
Abstract In a method for administering systemically active agents including therapeutic agents through the skin or other body membranes of humans and animals typically in the form of a transdermal device or formulation, the improvement comprising the use therewith of an effective amount of a membrane penetration enhancer having the structural formula. ##STR1## wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.
Inventors
- 👤 Vithal J. Rajadhyaksha
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 15:22
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K47/00; A61K47/06; A61K47/22; A61K8/00; A61K8/18; A61K8/30; A61K8/49; A61K8/4906; A61Q; A61Q19/00; A61F; A61F5/00; A61F5/41; A61F2005/415
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
65 words
In a method for topically administering systemically active agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation, the improvement comprising the topical administration of an effective amount of a membrane penetration enhancer having the structural formula ##STR3## where R is H or a lower alkyl group having 1-4 carbon atoms, m is 5 and n is 0-17.
Claim 2
Dependent Claim
65 words
In a method for topically administering systemically active agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation, the improvement comprising the topical administration of an effective amount of a membrane penetration enhancer having the structural formula ##STR3## where R is H or a lower alkyl group having 1-4 carbon atoms, m is 5 and n is 0-17.
Claim 3
Dependent Claim
9 words
The method of claim 1 wherein R is H.
Claim 4
Dependent Claim
9 words
The method of claim 2 wherein n is 0-11.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein the penetration enhancer is 1-dodecylazacycloheptan-2-one.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein the systemically active agent is a therapeutic agent.
Claim 7
Dependent Claim
10 words
The method of claim 5 wherein the administration is concurrent.
Claim 8
Dependent Claim
48 words
In a method for topically administering a systemically active therapeutic agent through the skin of a human in a transdermal device or formulation to obtain therapeutic blood levels of the therapeutic agent, the improvement comprising the concurrent topical administration of an effective skin penetration enhancing amount of 1-dodecylazacycloheptan-2-one.
Claim 9
Dependent Claim
48 words
In a method for topically administering a systemically active therapeutic agent through the skin of a human in a transdermal device or formulation to obtain therapeutic blood levels of the therapeutic agent, the improvement comprising the concurrent topical administration of an effective skin penetration enhancing amount of 1-dodecylazacycloheptan-2-one.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-09-19 | 1987-03-21 | 1987-09-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-09-19 | 1991-03-21 | 1991-09-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-09-19 | 1995-03-21 | 1995-09-20 | $7700.00 | Window Closed / Lapsed |